Search

Your search keyword '"Pal, S.K."' showing total 1,275 results

Search Constraints

Start Over You searched for: Author "Pal, S.K." Remove constraint Author: "Pal, S.K."
1,275 results on '"Pal, S.K."'

Search Results

20. Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma

24. Prognostic significance of absolute lymphocyte count in patients with metastatic renal cell carcinoma receiving first-line combination immunotherapies: results from the International Metastatic Renal Cell Carcinoma Database Consortium

32. Review on Parameters Influencing the Rice Breakage and Rubber Roll Wear in Sheller

34. Non-invasive current collectors for improved current-density distribution during CO2 electrolysis on super-hydrophobic electrodes

41. Measurement of electrons from beauty-hadron decays in p-Pb collisions at s N N = 2.76 TeV

42. Long-Term Outcomes of Patients on a Phase II Prospective Trial of Oligometastatic Hormone-Sensitive Prostate Cancer Treated with Androgen Deprivation and External Beam Radiation

43. 1455P Characterization of patients with metastatic renal cell carcinoma achieving complete response to first-line therapies: Results from the international metastatic renal cell carcinoma database consortium (IMDC)

45. LBA68 Bempegaldesleukin (BEMPEG) plus nivolumab (NIVO) compared to the investigator’s choice of sunitinib or cabozantinib in previously untreated advanced renal cell carcinoma (RCC): Results from a phase III randomized study (PIVOT-09)

46. 1383P Genomic landscape of advanced prostate cancer patients with BRCA1 versus BRCA2 mutations as detected by comprehensive genomic profiling (CGP) of cell-free DNA (cfDNA)

47. 1479P Ultra-sensitive circulating tumor DNA (ctDNA) assay distinguishes partial response (PR) and complete response (CR) with immunotherapy in metastatic renal cell carcinoma (mRCC)

48. LBA66 IMmotion010: Efficacy and safety from the phase III study of atezolizumab (atezo) vs placebo (pbo) as adjuvant therapy in patients with renal cell carcinoma (RCC) at increased risk of recurrence after resection

49. 481P A phase I first-in-human study of XL092 in patients (pts) with locally advanced or metastatic solid tumors: Results from dose-escalation of XL092 alone and in combination with atezolizumab

50. 1464P The impact of impaired renal function on the effectiveness of first-line immuno-oncology combination therapies in metastatic renal cell carcinoma (mRCC): Results from the international metastatic RCC database consortium (IMDC)

Catalog

Books, media, physical & digital resources